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Pancreatic neuroendocrine tumors (PNETs) are heterogeneous neoplasms which represent only 2% 
of all pancreatic neoplasms by incidence, but 10% by prevalence. Genetic risk factors could have an 
important role in the disease aetiology, however only a small number of case control studies have 
been performed yet. To further our knowledge, we genotyped 13 SNPs belonging to the pleiotropic 
CDKN2A/B gene region in 320 PNET cases and 4436 controls, the largest study on the disease so far. 
We observed a statistically significant association between the homozygotes for the minor allele of the 
rs2518719 SNP and an increased risk of developing PNET (ORhom = 2.08, 95% CI 1.05–4.11, p = 0.035). 
This SNP is in linkage disequilibrium with another polymorphic variant associated with increased risk 
of several cancer types. In silico analysis suggested that the SNP could alter the sequence recognized 
by the Neuron-Restrictive Silencer Factor (NRSF), whose deregulation has been associated with the 
development of several tumors. The mechanistic link between the allele and the disease has not been 
completely clarified yet but the epidemiologic evidences that link the DNA region to increased cancer 
risk are convincing. In conclusion, our results suggest rs2518719 as a pleiotropic CDKN2A variant 
associated with the risk of developing PNETs.
Pancreatic neuroendocrine tumors (PNETs) are heterogeneous neoplasms which are generally considered rare 
with an incidence around 0.40 per 100,000 subjects/year1,2 but their incidence has more than doubled in the last 
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30 years1,3,4. PNETs represent only 2% of all pancreatic neoplasms by incidence, but 10% by prevalence2,5. PNETs 
have been poorly studied, due to their rarity, and compared to other cancer types very little is known regarding 
either environmental or genetic risk factors for their occurrence. The role of traditional cancer risk factors such as 
smoking and alcohol consumption seems controversial6–8. On the contrary, type two diabetes (T2D) and family 
history of cancer have been consistently associated with PNET risk7,8.
Therefore genetic risk factors may have a role in disease aetiology, at least in a subset of PNET cases. Despite 
this, the impact of the genetic variability in the disease incidence is poorly understood. Only a small number of 
case-control studies have been performed to uncover the genetic susceptibility to PNETs9–12 and no genome wide 
association study (GWAS) has been performed yet.
With the goal of further our knowledge on PNET susceptibility we have performed a case-control study con-
sidering the genetic variability of the CDKN2A/2B region. The selection of the region was motivated by a fairly 
large amount of evidences pointing to a key role of this locus in pancreatic cancer onset and prognosis. For exam-
ple CDKN2A is commonly mutated or de-regulated in both endocrine and exocrine pancreatic cancer13. Genetic 
polymorphisms in the locus have been reported to be associated with type two diabetes mellitus (T2DM), which 
is a one of the few suggested risk factors for PNETs14–16, suggesting a shared genetic background between T2DM 
and PNETs. Genetic variants belonging to the CDKN2A/2B region have been identified through GWAS as suscep-
tibility markers for several human traits and diseases, including a large number of tumor types17–24. In addition we 
have recently showed the association of the CDKN2A/2B-rs3217992 SNP with increased risk of pancreatic ductal 
adenoma carcinoma (PDAC)25. The pleiotropic role of this region is justified by its crucial role in the regulation 
of the cell cycle26,27. Finally in a manuscript investigating the genetic susceptibility to endocrine tumors (NETs) 
Ter-Minassian and colleagues have suggested the association of four SNPs (representing two independent signals 
because of high linkage disequilibrium (LD)) in this region and an increased risk of the disease11.
Our hypothesis was that common genetic variability at the locus could modulate the risk of developing 
PNETs, as it has been shown for other cancer types.
Results
Data filtering and quality control. The origin of the population by country is shown in Table 1. None 
of the SNPs were out of Hardy-Weinberg equilibrium (HWE) in controls (p > 0.05). A total of 311 subjects 
(17 PNET cases and 294 controls) were removed after genotyping because they had a call rate < 75%. After the 
removal of these subjects the average SNP call rate was 95.54% with a minimum of 89.79% (rs3731246) and a 
maximum of 99.15% (rs3218009). The quality control analysis showed a concordance rate of 99.68% between the 
duplicate samples. After exclusions, 320 cases and 4,436 controls were used for statistical analyses.
SNPs main effect. We observed a statistically significant association between the carriers of the A allele of 
the rs2518719 SNP and an increased risk of developing PNET (ORhom = 2.08, 95% CI 1.05–4.11, p = 0.035). The 
association was statistically significant only comparing the rare and common homozygous individuals. None of 
the other SNPs showed any statistically significant associations. The frequencies and distributions of the geno-
types, the odds ratios (ORs) for the association of each polymorphism with PNET risk and relative confidence 
intervals (CI) are shown in Table 2.
Possible functional effects. We used several bioinformatic tools to predict possible functional relevance 
for the SNPs showing the most significant associations. RegulomeDB showed a score of 4 suggesting the pres-
ence of a transcription factor binding motif and a DNase sensitivity peak for rs2518719. HaploReg also sug-
gested the presence of a DNase sensitivity peak and the polymorphism to alter the sequence recognized by the 
Neuron-Restrictive Silencer Factor (NRSF) regulatory repressor. No significant association between rs2518719 
and expression of any gene is reported in the GTEx project. We used The SNAP software to find SNPs in LD 
with rs2518719 and we found 9 variants that had a minimum LD of 0.760 (rs2188127, rs3731222, rs3731217, 
Cases Controls
Region
 Germany 39 2,282
 Greece 23 175
 Northern Italy 88 595
 Central Italy 146 549
 Southern Italy 11 500
 Poland 13 335
 Total 320 4,436
Sex
 Male 162 2,305
 Female 156 2,071
Median age 58 58
(interquartile range) (48–66) (47–64)
Table 1.  Study population.
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rs3731204, rs3731198, rs2811711, rs495490, rs575427, rs647188) but also for them there was no evidence of 
association with gene expression in GTEx.
Discussion
The background of common genetic susceptibility to sporadic PNETs is largely unknown. The rarity of the dis-
ease is certainly one motivation for the scarcity of the information on the disease genetic susceptibility. Only 
a small number of studies have been performed with the largest study having 101 cases and 432 controls11. To 
further our understanding on the topic we conducted the largest study on the disease, with up to 320 cases and 
4,436 controls, taking advantage of the mainframe of the Pancreatic Disease Research (PANDoRA) Consortium. 
The only finding of potential significance was that the carriers of the rare A allele of the rs2518719 SNP had an 
increased risk of developing the disease. This SNP belongs to the CDKN2A gene and lies in the second intron of 
the gene around 2000 bp from the start of the 3′ UTR. Rs2518719 is in tight LD with another variant in the gene, 
rs3731217 (r2 = 0.925, D’ = 1 in Caucasian, as reported by 1000 Genomes), that lies in the first intron of the gene. 
This latter SNP is a well known pleiotropic susceptibility polymorphism and it has been found to be associated 
with increased risk of developing childhood acute lymphoblastic leukemia28,29, differentiated thyroid carcinoma30 
and salivary gland carcinoma31. In addition the SNP was also reported to modulate the survival of oropharingeal 
cancer patients32. Despite all these evidences, indicating a role of the variant allele in developing various diseases, 
no functional studies have been performed and therefore it is not possible to elucidate a possible direct effect of 
the SNP. It has been suggested that rs3731217 might be involved in the regulation of the p53 gene expression, but 
given the before mentioned lack of direct functional evidence this remains highly speculative32.
The observation that it is always the same allele, in different cancer types, to be associated with an increased 
risk indicates a pleiotropic role for rs2518719/rs3731217 (or one of the other variants in tight LD) and also 
strongly suggests that the causal variant alters the function of the protein, the regulation of the gene expression 
or both in a way that influences the chances of developing cancer in different organs. The 9p21.3 locus in general, 
and the CDKN2A/CDKN2B genes in specific, are a classic examples of pleiotropic regions since they are associ-
ated with a very large number of human traits and diseases17–19,22–24. Pleiotropic regions are probably more acces-
sible DNA stretches than normal and therefore variability within them may result to be non neutral more likely 
than in any other randomly selected DNA sequence. However the regulation of pleiotropic region is likely to be 
more complex than other genome parts and therefore this increases the difficulties in understanding the effect of 
the genetic effect at each single locus.
The results from HaploReg suggested that rs2518719 could alter the sequence recognized by the NRSF regu-
latory repressor. NRSF is encoded by the RE1-Silencing Transcription factor (REST) gene, and its deregulation 
has been associated to the development of several tumors including colon and lung cancer33. Therefore a possible 
explanation of the pleiotropic valence of this SNP may rely on the regulatory effect of the sequence recognized 
by NRSF/REST. However, even if it is intriguing, also this functional explanation remains speculative especially 
considered that NRSF is primarily involved in the silencing of neural genes in non neuronal tissues34. The lack of 
reliable functional data and eQTLs for the SNP can be explained by the fact that the entire CDKN2A/2B region is 
under a very complex gene regulation.
The results from Ter-Minassian and colleagues, in their study on neuroendocrine tumors, are in agreement with 
what we found suggesting, also in their case, an increased risk specifically of PNET for individuals carrying the rare 
allele for rs2518719 and the linked rs3731217 and rs373119811. In that paper the authors also observed an independ-
ent signal from the rs3731211 variant. Considering our sample size and their ORs we had a power greater than 99% of 
finding the association but we did not. Considering also the p value reported (p = 0.042) the most likely explanation 
for this discrepancy is that the association was due to statistical fluctuation due to the rarity of the disease.
SNP




Casesb Controlsb MM vs Mm MM vs mm MM vs Mm + mm
MM Mm mm MM Mm mm ORc 95% CIc p ORc 95% CIc p ORc 95% CIc p
rs3731257 21,956,221 C/T 166 130 21 2,243 1,700 290 1.07 0.81–1.40 0.640 0.86 0.49–1.53 0.610 1.04 0.80–1.35 0.786
rs11515 21,958,199 C/G 235 83 3 3,065 1,114 108 1.03 0.77–1.39 0.834 0.28 0.07–1.14 0.076 0.95 0.71–1.28 0.758
rs2518719 21,960,427 G/A 228 78 10 3,217 996 93 1.07 0.78–1.47 0.671 2.08 1.05–4.11 0.035 1.16 0.86–1.56 0.336
rs3731249 21,960,916 C/T 295 27 0 3,484 310 9 1.06 0.66–1.70 0.815 N/A 1.16 0.63–1.63 0.949
rs3731246 21,961,989 C/G 237 61 2 1,630 450 29 0.89 0.62–1.26 0.501 0.57 0.14–2.43 0.451 0.87 0.61–1.22 0.412
rs2811708 21,963,422 T/G 160 126 27 2,200 1,633 304 1.14 0.86–1.51 0.354 1.20 0.73–1.97 0.463 1.15 0.88–1.50 0.299
rs3731239 21,964,218 C/T 132 147 36 1,851 1,909 534 1.06 0.80–1.40 0.700 0.84 0.53–1.33 0.455 1.01 0.77–1.32 0.944
rs3731211 21,976,847 A/T 144 132 30 1,844 1,457 340 1.21 0.91–1.61 0.191 1.15 0.715–1.83 0.572 1.20 0.91–1.57 0.193
rs2811710 21,981,923 T/C 127 150 42 1,086 1,336 433 0.97 0.73–1.30 0.842 0.96 0.64–1.44 0.835 0.97 0.74–1.27 0.814
rs3218009 21,988,757 C7G 270 51 1 3,541 728 50 1.01 0.71–1.43 0.965 0.38 0.05–2.82 0.346 0.96 0.68–1.37 0.862
rs3217992 21,993,223 G/A 98 163 57 1,456 2,068 723 1.07 0.80–1.44 0.649 1.04 0.70–1.54 0.862 1.06 0.80–1.41 0.675
rs1063192 21,993,367 G/A 119 139 50 1,436 1,809 549 0.95 0.71–1.28 0.738 1.27 0.86–1.87 0.227 1.02 0.78–1.35 0.865
rs3217986 21,995,330 C/A 283 35 3 3,672 671 24 0.68 0.44–1.03 0.066 2.45 0.72–8.35 0.153 0.73 0.49–1.09 0.124
Table 2.  Associations between selected SNPs in the CDKN2A/2B region and PNET risk. aM: major allele; 
m: minor allele. bNumbers may not add up to the total of available subjects due to genotyping failure. cOR: odds 
ratio; CI: confidence interval. All analyses were adjusted by age, sex and geographical region of origin. Results in 
bold are statistically significant (p < 0.05).
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In the light of multiple testing this association is not statistically significant, however considering the con-
cordance with previous reports and the low statistical power permitted by the rarity of the disease a Bonferroni 
correction is too strict. We therefore used also the False Positive Report Probability (FPRP35) and using a prior of 
0.25 the association retains noteworthiness (posterior p = 0.188). We used a prior p = 0.25 based on the fact that 
the polymorphism is pleiotropic or in almost complete LD with one, and that it has been found to be associated 
already with PNET risk. We are aware that the results given by the FPRP are indications and that the final confir-
mation of the association can be only given by functional studies.
The present study carries some limitation, such as limited clinical information on the sporadic PNETs patients 
in terms of environmental and familial risk factors and disease stage and grade. However, our results, taken 
together with what found by Ter-Minassian and colleagues convincingly suggest that the pleiotropic CDKN2A 
region is associated with the risk of developing PNETs as already observed for several other cancer types.
Materials and Methods
Study population. In the present study 320 sporadic PNET patients and 4,436 controls belonging to the 
Pancreatic Disease Research (PANDoRA) consortium were recruited in 4 European countries. Cases were spo-
radic, i.e. not observed in the context of genetic syndromes associated with PNET, such as MEN-1, MEN-2, VHL 
or TSC. Controls were recruited in the same hospitals, or at least geographical region from where the cases were 
recruited. All participants signed a written consent form. The study protocol was approved by the ethic board of 
the University of Heidelberg and was carried out according to declaration of Helsinki. Additional information on 
the PANDoRA consortium have been given elsewhere36.
SNPs selection. We investigated the common genetic variability in the CDKN2A/B region using tagging 
SNPs and potentially functional SNPs. Tagging SNPs were selected using a pairwise tagging method with a mini-
mum r2 of 0.8 and a minor frequency allele of 0.05. We identified 11 SNPs that efficiently tagged the selected gene 
region. Subsequently we added two (rs1063192 and rs3217992) putative miR-SNPs that are polymorphic variants 
predicted to alter the binding of one or more microRNAs to their target. Therefore the final selection resulted in 
13 SNPs.
Sample preparation and genotyping. For each sample DNA was extracted from whole blood using the 
AllPrep Isolation Kit (Qiagen, Hilden, Germany) or the Qiagen-mini kit (Qiagen, Hilden, Germany), according 
to the manufacturer’s protocol. Blood was kept frozen before the extraction. Genotyping was performed using 
KASP (KBioscence, Hoddesdon, UK) and TaqMan (Thermo Fisher Scientific, Waltham, MA, USA) technologies. 
Genotyping was carried out using 384 well plates using 5ng of DNA for each sample. The order of DNA samples 
was randomized on plates in order to ensure that similar numbers of cases and controls were analyzed in each 
batch. Detection was performed using an ABI PRISM Viia7 sequence detection system with Viia7 software (Applied 
Biosystems, Foster City, CA, USA). The personnel performing the genotyping was blinded on the identity of the 
subject (i.e. whether the DNA belonged to a case or a control subject). For quality control, duplicates of 10% of the 
samples were interspersed throughout the plates. In addition, we discarded all the samples that had a call rate < 75%.
Statistical analysis. Using Pearson’s chi-square test we checked the departure from Hardy–Weinberg equi-
librium (HWE) for all SNPs in the control subjects of the study. Unconditional logistic regression computing odds 
ratios (OR), 95% confidence intervals (95% CIs) and p values was used to estimate the association between the 
genotypes of all polymorphisms and PNET risk. The more common allele among the controls was assigned as the 
reference category and the co-dominant model inheritance model was assessed. All analyses were adjusted for 
age, gender and geographic origin.
Multiple testing. We used two methods to correct for multiple testing: a robust conservative test and a 
Bayesian one. The threshold to declare an association to be significant with a Bonferroni correction is 0.0038 
(0.05/13). Considering the vast a priori knowledge on the region and on the SNPs in particular we opted to 
use also the False Positive Report Probability (FPRP) method. The FPRP was developed by Wacholder and col-
leagues35 to assess if an association is ‘noteworthy’ using a Bayesian approach that includes a priori knowledge 
of the variable taken in consideration. For associations with moderate to high prior evidence (e.g. association 
reported in a previous study, convincing functional evidence) the prior probabilities used are in the range 0.10–
0.25, whereas lower prior probabilities are employed with decreasing information on the SNP and/or the relation 
between the SNP and the disease35,37.
Bioinformatic analysis. We used several bioinformatic tools to assess the possible functional relevance for 
the SNP showing the most significant association with risk of developing PNET. RegulomeDB (http://regulome.
stanford.edu/)38 and HaploReg v2B39 were used to identify the regulatory potential of the region nearby each SNP. 
The GTEx portal web site40 was used to identify potential associations between the SNP and expression levels of 
nearby genes (eQTL). In addition we used the SNAP software41 to find SNPs in LD with the SNP that showed the 
strongest association with PNET risk using a threshold of r2 = 0.70.
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